Q-omics provides the consensus-scored LINC00670 profile across patient tissues and cancer cell-line models. LINC00670 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, LINC00670 is differentially expressed in 10, with the highest sampling consensus in BLCA. Additionally, LINC00670 RNA expression shows 11,754 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight KIRP, BLCA, and LUAD as cancer lineages where LINC00670 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC00670 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC00670 survival associations across molecular data types. LINC00670 RNA expression shows survival associations in the most cancer types (17), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC00670 RNA expression–survival associations across cancer types. High LINC00670 expression shows unfavorable associations in KIRP, THCA, READ and CHOL, but favorable associations in ESCA and ACC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for LINC00670 RNA expression.
This table summarizes LINC00670 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for LINC00670. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC00670 shows lower tumor expression in BLCA, LUSC, KICH, LUAD, UCEC and BRCA. The BLCA box plot shows higher LINC00670 RNA expression in normal versus tumor tissue (log2 FC = −0.196, t-test p = .003).
This table shows molecular features associated with LINC00670 in patient tissues and cancer cell lines. In patient samples, LINC00670 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, LINC00670 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in SKIN.
